---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-045573"
form_type: "8-K"
ticker: "ELOX"
cik: "0001035354"
company_name: "Eloxx Pharmaceuticals, Inc."
filed_at: "2023-04-14T23:59:59+00:00"
generated_at: "2026-06-17T01:46:22.600105+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Eloxx receives Nasdaq delisting notice for failing to maintain $35M market value

## Summary
- Received delisting notice on April 11, 2023, for non-compliance with Nasdaq's $35M minimum market value requirement.
- Company failed to regain compliance during the 180-day grace period that ended April 10, 2023.
- Trading will be suspended on April 20, 2023, unless company requests a hearing by April 18, 2023.
- Company intends to appeal; a hearing request will stay the suspension pending Panel decision.
- There is no assurance the appeal will succeed or that continued listing will be granted.

## SEC filing metadata
- accession: 0001104659-23-045573
- form_type: 8-K
- ticker: ELOX
- cik: 0001035354
- company_name: Eloxx Pharmaceuticals, Inc.
- filed_at: 2023-04-14T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1035354/000110465923045573/0001104659-23-045573-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1035354/000110465923045573/tm2312848d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-045573
- JSON: https://secwatch.observer/filing/0001104659-23-045573.json
- Plain text: https://secwatch.observer/filing/0001104659-23-045573.txt

## Key facts
- Listing & Compliance Notices
  Eloxx Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: market value
  - Rules: 5550(b)(2)
  source text: April 11, 2023, Eloxx Pharmaceuticals, Inc. (the “ Company ”) received a determination letter (the “ Letter ”) from the staff (the “ Staff ”) of the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) stating that the Company has not regained compliance with Listing Rule 5550(b)(2) (the “ Minimum Market Value Requirement ”), requiring the Company to maintain a Market Value of Listed Securities of a minimum of $35 million, during the 180-day grace period previously granted to the Company. As previously disclosed, the Company was initially notified by the Staff on Octob
  evidence_url: https://www.sec.gov/Archives/edgar/data/1035354/000110465923045573/0001104659-23-045573-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.